Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 21, 2019 14:41 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Receives Formulation Patent Notice of Allowance

New York, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
May 17, 2019 13:25 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Receives Best Private Company Presentation Award at BioNJ’s 9th Annual BioPartnering Conference

New York, May 17, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing patient-friendly food allergy therapies for peanut and other food allergies...
March 08, 2019 10:01 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy for Food Allergy

New York, March 08, 2019 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
November 08, 2018 16:44 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Announces First Close of Series A Preferred Equity Financing and Successful Close of Crowdfunding Financing Campaign to Support New Peanut Allergy Treatment

New York, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, is...
September 06, 2018 07:11 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Completes Pre-IND Meeting With FDA on INT301 for Peanut Allergy

New York, Sept. 06, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
May 15, 2018 12:00 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week

New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food...
May 09, 2018 10:36 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Announces Crowdfunding Financing Campaign to Support Food Allergy Treatment Research

New York, May 09, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics is pleased to announce the launch of a crowdfunding campaign on the Netcapital platform. This campaign supports the next steps of...
April 24, 2018 09:27 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics to Present at Eighth Annual BioNJ BioPartnering Conference

New York, April 24, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, announced today that it...
June 14, 2016 07:30 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics Announces Expansion of Advisory Board with Three Top Food Allergy Experts

New York, June 14, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...
June 06, 2016 07:55 ET | Source: Intrommune Therapeutics

Intrommune Therapeutics to Present at 2016 BIO International Convention

New York, June 06, 2016 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a specialty biopharmaceutical company developing a patient-friendly platform for the treatment of food allergies, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right